EGFR and lung cancer: In conclusion, we report stable and multifunctional nanostructured lipid carriers (NLCs) comprised of therapeutic agents (anticancer drugs and human EGFR siRNA), imaging agents (fluorophore), and targeting agents (LHRH peptide) for the delivery of therapeutics specifically to human lung cancer cells.